Generation Bio
GBIO
GBIO was delisted on the 6th of February, 2026.
94 hedge funds and large institutions have $223M invested in Generation Bio in 2022 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 40 increasing their positions, 28 reducing their positions, and 25 closing their positions.
1,575% more call options, than puts
Call options by funds: $67K | Put options by funds: $4K
43% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 28
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.38% less ownership
Funds ownership: 97.79% → 95.4% (-2.4%)
15% less funds holding
Funds holding: 111 → 94 (-17)
27% less capital invested
Capital invested by funds: $306M → $223M (-$83.6M)
60% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.44M |
| 2 |
Vontobel Holding
Zurich,
Switzerland
|
+$1.44M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.36M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$1.04M |
| 5 |
YCM
Yiheng Capital Management
San Francisco,
California
|
+$989K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$6.57M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$1.36M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$706K |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$580K |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
-$578K |
GBIO Hedge Fund Activity: Q4 2022 in Review
94 of the 6,239 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q4 2022, worth a combined $223M — down 27% from $306M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of GBIO and 10 opened new positions — a net loss of 15 holders — while 28 trimmed existing stakes and 40 added.
The largest buyer was Sectoral Asset Management, opening a new position worth an estimated $1.44M. The largest seller was Farallon Capital Management, cutting an estimated $6.57M.
- 94 institutional investors held Generation Bio (GBIO) as of Q4 2022, down from 111 in Q3 2022.
- Funds reported $223M of Generation Bio stock for Q4 2022, down 27% quarter-over-quarter.
- 10 funds opened new Generation Bio positions in Q4 2022 and 25 closed out, a net change of -15 holders.
- The largest Generation Bio buyer in Q4 2022 was Sectoral Asset Management, an estimated $1.44M added.
- The largest Generation Bio seller in Q4 2022 was Farallon Capital Management, an estimated $6.57M sold.
Based on aggregated 13F filings for Q4 2022.